The study, backed by the nonprofit T1D Exchange, involved 226 adults with type 1 diabetes. All participants were given a Dexcom’s G4 Continuous Glucose Monitoring System to use for six months. During the study period, 149 participants used the Dexcom system alone and 77 used both the continuous glucose monitoring system and a blood measurement via fingerstick testing. Researchers detected no difference in outcomes between the two cohorts.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox
“This study is an important step to support regulatory pathways for the automation of insulin delivery for people with type 1 diabetes,” said Dana Ball, executive director and co-founder of T1D Exchange. “These data are supportive of the recent [Food and Drug Administration] decision to approve the Dexcom G5 indication for insulin dosing and removes a key obstacle that has prevented reimbursement of continuous glucose monitoring by Medicare.”
In December 2016, the FDA approved the Dexcom system as supplementary to blood testing, but not as a replacement.
More articles on quality:
DOJ, CMS: Texas governor’s hiring freeze could put mentally disabled patients at risk
The Kennedy Center teams up with NIH to investigate link between music and health
5 things to know about upcoming Patient Safety Awareness Week
